Susmed (TSE:4263) Enterprise Value: 円10,222.8 Mil (As of Jul. 06, 2026) ***


TSE:4263 Susmed Inc TSE:4263
69 GF Score
Price 円818.00
GF Value 円974.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Susmed Enterprise Value?

Susmed TSE:4263 -2.73% 69 Enterprise Value is 円10,222.8 Mil as of Jul. 06, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円974.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Susmed's Enterprise Value is 円10,222.8 Mil. Susmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円-497.2 Mil. Therefore, Susmed's EV-to-EBIT ratio for today is -20.56.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Susmed's Enterprise Value is 円10,222.8 Mil. Susmed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円-489.2 Mil. Therefore, Susmed's EV-to-EBITDA ratio for today is -20.90.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Susmed's Enterprise Value is 円10,222.8 Mil. Susmed's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円275.2 Mil. Therefore, Susmed's EV-to-Revenue ratio for today is 37.14.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Susmed's Enterprise Value is 円10,222.8 Mil. Susmed's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.0 Mil. Therefore, Susmed's EV-to-OCF ratio for today is .

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Susmed's Enterprise Value is 円10,222.8 Mil. Susmed's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.0 Mil. Therefore, Susmed's EV-to-FCF ratio for today is .

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Susmed  (TSE:4263) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Susmed's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10222.822/-497.188
=-20.56

Susmed's current Enterprise Value is 円10,222.8 Mil.
Susmed's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-497.2 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Susmed's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10222.822/-489.213
=-20.90

Susmed's current Enterprise Value is 円10,222.8 Mil.
Susmed's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-489.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Susmed's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10222.822/275.248
=37.14

Susmed's current Enterprise Value is 円10,222.8 Mil.
Susmed's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円275.2 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Susmed's EV-to-OCF for today is:


Susmed's current Enterprise Value is 円10,222.8 Mil.
Susmed's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Susmed's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10222.822/0
=

Susmed's current Enterprise Value is 円10,222.8 Mil.
Susmed's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Susmed Enterprise Value Related Terms


Susmed Enterprise Value Historical Data

* Premium members only.

The historical data trend for Susmed's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed Enterprise Value Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Enterprise Value
Get a 7-Day Free Trial 0.00 9,806.43 24,606.59 5,208.48 5,877.05

Susmed Quarterly Data
Jun20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,627.83 5,373.56 5,877.05 10,222.71 12,280.03

TSE:4263 vs VEEV, BTSG, TEM: Enterprise Value Comparison

For the Health Information Services subindustry, Susmed's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Susmed Enterprise Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Susmed's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Susmed's Enterprise Value falls into.


TSE:4263
69GF Score
Susmed Inc TSE:4263
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Susmed's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as

Susmed's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of 円10,222.8 Mil mean?
Susmed (TSE:4263) has a Enterprise Value of 円10,222.8 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Susmed and its competitors.
Is Susmed's Enterprise Value too high?
Susmed's current Enterprise Value is 円10,222.8 Mil. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Enterprise Value compare to VEEV and BTSG?
Susmed's Enterprise Value of 円10,222.8 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Susmed and its competitors. Susmed's current Enterprise Value is 円10,222.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円974.33, compared to a current price of 円818.00 — trading 16% below its estimated fair value. The current Enterprise Value is 円10,222.8 Mil. Susmed's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Susmed (TSE:4263), the current Enterprise Value is 円10,222.8 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円818.00 is trading 16% below its estimated GF Value™ of 円974.33. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • Enterprise Value: 円10,222.8 Mil
  • GF Value™: 円974.33 vs. price of 円818.00 (16% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score

Get the complete analysis for TSE:4263

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円818.00
Price
円974.33
GF Value